Author: Kim, Eu Suk; Choe, Pyoeng Gyun; Park, Wan Beom; Oh, Hong Sang; Kim, Eun Jung; Nam, Eun Young; Na, Sun Hee; Kim, Moonsuk; Song, Kyoung-Ho; Bang, Ji Hwan; Park, Sang Won; Kim, Hong Bin; Kim, Nam Joong; Oh, Myoung-don
Title: Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection Document date: 2016_9_2
ID: vehb7dal_24
Snippet: This study has some limitations. Small numbers of patients were included and five patients had concurrent infectious diseases, which might affect the clinical course and laboratory features of MERS-CoV infection. Nine patients received pegylated INF-α2a, which could affect serum level of INF-α and other cytokine profiles through cytokine feedback cascades. However, in each group the IL-6 and CXCL-10 profiles were similar regardless of the admin.....
Document: This study has some limitations. Small numbers of patients were included and five patients had concurrent infectious diseases, which might affect the clinical course and laboratory features of MERS-CoV infection. Nine patients received pegylated INF-α2a, which could affect serum level of INF-α and other cytokine profiles through cytokine feedback cascades. However, in each group the IL-6 and CXCL-10 profiles were similar regardless of the administration of pegylated INF-α2a. Also subset analysis including the patients who did not received interferon therapy showed similar trends ( Supplementary Fig. 4 ). In spite of these limitations, this study has strengths in that we collected clinical data and serum samples serially in prospective manner and diverse cytokine or chemokine levels were measured in this newly emerging disease.
Search related documents:
Co phrase search for related documents- clinical course and cytokine profile: 1, 2, 3, 4, 5, 6, 7
- clinical course and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical course and interferon therapy: 1, 2
- clinical course and laboratory feature: 1, 2
- clinical course and limitation spite: 1
- clinical course and MERS cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical course and MERS cov infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- concurrent infectious disease and infectious disease: 1, 2, 3, 4, 5, 6, 7
- cytokine feedback and infectious disease: 1
- cytokine profile and infectious disease: 1, 2
- cytokine profile and MERS cov: 1, 2, 3, 4, 5, 6, 7
- cytokine profile and MERS cov infection: 1
- diverse cytokine and infectious disease: 1
- infectious disease and interferon therapy: 1
- infectious disease and MERS cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- infectious disease and MERS cov infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- interferon therapy and MERS cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- interferon therapy and MERS cov infection: 1, 2, 3, 4, 5, 6
- laboratory feature and MERS cov infection: 1
Co phrase search for related documents, hyperlinks ordered by date